GlassScriptPhysician profile
Nikhil R Asher
NPI 1831366129
$1,227.58
in general payments reported to CMS, 2019-2025
15 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.33 · 2022: $16.93 · 2023: $484 · 2024: $360 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.34 | 2023-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $164.81 | 2024-2025 | Airsupra |
| Abiomed | $142.11 | 2024 | Impella |
| Novo Nordisk INC | $136.13 | 2022-2025 | Wegovy |
| Alkermes, INC. | $129.12 | 2023-2025 | Vivitrol, Vivitrol |
| Getinge USA Sales, LLC | $95.64 | 2024 | Cardiohelp |
| Amgen INC. | $38.50 | 2023-2025 | Evenity, Prolia, Prolia |
| Inari Medical, INC. | $23.67 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Daiichi Sankyo INC. | $22.40 | 2023 | Injectafer |
| Lilly USA, LLC | $21.68 | 2025 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.81 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $14.67 | 2024 | Contrave, Onzetra Xsail |
| Antares Pharma, INC. | $14.39 | 2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $13.98 | 2025 | |
| Gilead Sciences, INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.